Blueprint Medicines Corp (NASDAQ:BPMC) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Boasting a price of $28.56, Blueprint Medicines Corp (NASDAQ:BPMC) traded -1.98% lower on the day. With the last stock price close up 35.81% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Blueprint Medicines Corp has recorded a 50-day average of $28.13 and a two hundred day average of $21.91. Volume of trade was up over the average, with 275,722 shares of BPMC changing hands over the typical 187,172
Zacks Investment Research has downgraded Blueprint Medicines Corp (NASDAQ:BPMC) to Sell in a statement released on 10/11/2016.
On 10/07/2016, Zacks Investment Research released a statement for Blueprint Medicines Corp (NASDAQ:BPMC) bumped up the target price from $0.00 to $31.00 that suggested an upside of 0.12%.
With a total market value of $0, Blueprint Medicines Corp has with a one year low of $13.04 and a one year high of $30.90 .
A total of 3 equity analysts have released a ratings update on BPMC. One equity analyst rating the company a strong buy, two equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $31.00.
Brief Synopsis About Blueprint Medicines Corp (NASDAQ:BPMC)
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company's drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.